{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field 48939978-7054-48f6-8753-a99e00f858ba --><h2>What else might it be?</h2><!-- end field 48939978-7054-48f6-8753-a99e00f858ba -->","summary":"","htmlStringContent":"<!-- begin item fedec078-cfa0-490e-ae67-a99e00f8584e --><!-- begin field 795e206d-76ad-43b4-afae-a99e00f858ba --><ul><li>The differential diagnosis of acute pyelonephritis is broad, and includes:<ul><li>Acute abdominal conditions — especially if nausea and vomiting are prominent. </li><li>Acute prostatitis — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/prostatitis-acute/\">Prostatitis - acute</a>. </li><li>Gynaecological conditions — however, typically there is no tenderness in the costovertebral region. </li><li>Musculoskeletal disorders — suspect when costovertebral pain is a conspicuous feature. </li><li>Lower lobe pneumonia — symptoms include cough and pleuritic chest pain. Physical examination may show decreased breath sounds, rales, or rhonchi. </li><li>Lower urinary tract infection — for more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/urinary-tract-infection-lower-men/\">Urinary tract infection (lower) - men</a> and <a class=\"topic-reference external-reference\" href=\"/topics/urinary-tract-infection-lower-women/\">Urinary tract infection (lower) - women</a>.</li><li>Pelvic inflammatory disease — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pelvic-inflammatory-disease/\">Pelvic inflammatory disease</a>.  </li><li>Pelvic pain syndrome — recurrent symptoms, including dysuria, pain on intercourse, and pelvic pain, occur with negative cultures. </li><li>Shingles — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/shingles/\">Shingles</a>. </li></ul></li></ul><!-- end field 795e206d-76ad-43b4-afae-a99e00f858ba --><!-- end item fedec078-cfa0-490e-ae67-a99e00f8584e -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"c9d87f4c-6f88-54aa-9c09-0ec6ad893b08","slug":"basis-for-recommendation-57f","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 8598b90e-0e43-4249-b678-a99e00f8eb09 --><h3>Basis for recommendation</h3><!-- end field 8598b90e-0e43-4249-b678-a99e00f8eb09 -->","summary":null,"htmlStringContent":"<!-- begin item 57f3ad8e-5ed4-4df2-bac8-a99e00f8eadb --><!-- begin field 413c285e-f536-49c8-9c35-a99e00f8eb09 --><p>These recommendations are based on the British Medical Journal (BMJ) best practice guide <em>Acute pyelonephritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BMJ, 2018</a>], and expert opinion in a narrative review <em>Pyelonephritis can lead to life-threatening complications</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Keenan, 2017</a>]. </p><!-- end field 413c285e-f536-49c8-9c35-a99e00f8eb09 --><!-- end item 57f3ad8e-5ed4-4df2-bac8-a99e00f8eadb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}